Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Cell and Molecular Biology, Faculty of Life Sciences and Technology, Shahid Beheshti University G.C., Tehran, Iran.
Biomed Pharmacother. 2021 Mar;135:111217. doi: 10.1016/j.biopha.2021.111217. Epub 2021 Feb 1.
Osteosarcoma is rare malignancy of childhood and adolescence, with high morbidity and mortality despite accomplishment of diverse therapeutic modalities. Identification of the underlying mechanism of osteosarcoma evolution would help in better management of this rare malignancy. Lots of investigations have described abnormal regulation of long non-coding RNAs (lncRNAs) in clinical specimens of osteosarcoma and the established cell lines. This malignancy has been associated with over-expression of TUG1, LOXL1-AS1, MIR100HG, NEAT1, HULC, ANRIL and a number of other lncRNAs, while under-expression of lots of lncRNAs including LncRNA-p21, FER1L4, GAS5, LncRNA NR_136400 and LINC-PINT. Expression amounts of LUCAT1, LINC00922, SNHG12, FOXC2-AS1 and OIP5-AS1 lncRNAs have been associated with response to a number of chemotherapeutic agents. Taken together, lncRNAs are possible targets for proposing novel advanced therapeutic modalities for osteosarcoma.
骨肉瘤是儿童和青少年罕见的恶性肿瘤，尽管采用了多种治疗方法，但其发病率和死亡率仍然很高。鉴定骨肉瘤演变的潜在机制将有助于更好地管理这种罕见的恶性肿瘤。大量研究已经描述了骨肉瘤临床标本和已建立的细胞系中长链非编码 RNA（lncRNA）的异常调节。这种恶性肿瘤与 TUG1、LOXL1-AS1、MIR100HG、NEAT1、HULC、ANRIL 和许多其他 lncRNA 的过表达有关，而许多 lncRNA 的表达水平下调，包括 LncRNA-p21、FER1L4、GAS5、LncRNA NR_136400 和 LINC-PINT。LUCAT1、LINC00922、SNHG12、FOXC2-AS1 和 OIP5-AS1 lncRNA 的表达量与对许多化疗药物的反应有关。综上所述，lncRNA 可能是提出骨肉瘤新的先进治疗方法的潜在靶点。
